

MEETING VENUE

Hotel Splendid
Via Sempione, 12 - 28831 Baveno (VB)
T: 0039 0323 92 45 83

PROGRAM DIRECTOR AND SCIENTIFIC COORDINATOR

Savino Bruno
Full Professor of Medicine
Humanitas University Medicine (HUNIMED)
Director of the Department of Internal Medicine
IRCCS Istituto Clinico Humanitas – Rozzano, Milano

ACCREDITAMENTO ECM

Questo Convegno darà diritto a n. 11.5 crediti ECM per l'anno 2015.
Il Convegno è accreditato per la professione "Medico Chirurgo"
Discipline di riferimento: Gastroenterologia/Epatologia, Malattie Infettive, Chirurgia Generale, Medicina Interna, Microbiologia e Virologia. Per la certificazione ECM è assolutamente indispensabile compilare in ogni sua parte (in particolare nome e cognome, data e luogo di nascita, codice fiscale, indirizzo e-mail e numero di iscrizione all'Ordine/Collegio Professionale) il Modulo Dati ECM, la Scheda di Valutazione ed il Questionario di Apprendimento. Durante il Convegno i partecipanti dovranno registrare la propria presenza in aula ad inizio e fine lavori.

ATTENZIONE: Per conseguire i crediti formativi sarà necessario garantire la propria presenza al 100% del tempo totale, rispondere correttamente al 75% delle domande contenute nel questionario di valutazione dell'apprendimento, compilare tutta la modulistica e riconsegnarla al termine del Convegno alla postazione ECM presso la Segreteria.

ORGANIZING SECRETARIAT:



Start Promotion Srl
Via Mauro Macchi, 50
20124 Milano
T: 0039 02 67 07 13 83
F: 0039 02 67 07 22 94
www.startpromotion.it
info@startpromotion.it

Con il supporto non condizionante di



INFC-1151158-0000-PEG-C-05/2017

Esemplare fuori commercio.
Omaggio per i Sigg medici.



th

EXPERT MEETING on the Management of Patients with HCV INFECTION

Baveno, Italy - September 17/18 2015

SCIENTIFIC RATIONALE

The hepatitis C virus represents, and is expected to represent in the near future, one of the major causes of chronic liver disease in our country, also due to the current immigration flows. In this rapidly changing field, more and more drugs offer interesting treatment perspectives. However, pros and cons of universal vs. restricted treatment should be discussed, based on a cost analysis.

Moreover, in order to improve the choice of treatment schedules, on- and off-label combination results of new molecules in different clinical settings require a specific discussion. Not least, the residual role of currently available second wave PIs in combination with PEG and RBV in patients without cirrhosis should be assessed with a focus on cost-effectiveness.

The Meeting is targeted to specialists in Internal Medicine, Hepatology, Gastroenterology, and Infectious Diseases, aiming to provide them with the opportunity to interact with the Experts and discuss all the clinical issues of chronic hepatitis C and its complications.

FACULTY

Alessio Aghemo	Milano	Carlo Cammà	Palermo
Tarik Asselah	Paris, France	Alessia Ciancio	Torino
Alfredo Alberti	Padova	Massimo Colombo	Milano
Marc Bourliere	Marseilles, France	Antonio Craxi	Palermo
Raffaele Bruno	Pavia	Donald Jensen	Chicago, Usa
Savino Bruno	Milano	Gloria Taliani	Roma

GROUPS

RED

Special populations: are they changed with new DAA's?

Tutor: **G. Taliani**

ORANGE

Drug Drug Interactions

Tutor: **R. Bruno**

GREEN

Cost-benefit evaluation of all-oral DAA's. Restricted vs widespread therapy. What is the best choice?

Tutor: **C. Cammà**

BLUE

How to manage comorbidities in the era of all oral regimens?

Tutor: **A. Ciancio**

BROWN

Patients with cirrhosis and G3 infection. A big challenge

Tutor: **S. Bruno**

BLACK

A review of International guidelines

Tutor: **A. Aghemo**

SCIENTIFIC PROGRAM - SEPTEMBER 17, 2015

12.00 - 12.30	Registration
12.30 - 14.30	Welcome Lunch
14.30 - 14.45	Course presentation S. Bruno
14.45 - 15.15	LECTURE: Treatment of cirrhotic patients in the era of DAA. Will SVR still remain an useful surrogate marker of disease outcome? M. Colombo
15.15 - 15.30	Coffee Break
15.30 - 18.45	WORKSHOPS: Red, Orange, Green, Blue, Brown, Black

SCIENTIFIC PROGRAM - SEPTEMBER 18, 2015

08.30 - 09.00	LECTURE: How can we fill the time-gap until the universal treatment will be delivered? Pharmacoeconomics and ethical consideration. A. Craxi
09.00 - 09.30	LECTURE: On- and off-label all-oral DAAs Light and shadow M. Bourliere
09.30 - 10.00	LECTURE: What's the better DAAs combination for patients who failed triple therapy with first generation PIs? T. Asselah
10.00 - 10.30	LECTURE: Updated results of TARGET and TRIO studies. Focus on both compensated and decompensated cirrhosis with or without failure of first generation PIs D. Jensen
10.30 - 11.00	New molecules on the horizon S. Bruno
11.30 - 12.00	LECTURE: The future for liver transplant without HCV A. Alberti
12.00 - 13.00	WORKSHOP RESULTS: Groups Red, Orange and Blue Chairperson: G. Taliani
13.00 - 14.00	Lunch
14.00 - 15.30	WORKSHOP RESULTS: Groups Brown, Black and Green Chairperson: S. Bruno
15.30 - 16.00	Discussion and Conclusion

6th
EXPERT MEETING
on the Management of
Patients with HCV INFECTION